Thematische Bibliographien / Hopital Henri Mondor (Créteil, France)

Auswahl der wissenschaftlichen Literatur zum Thema „Hopital Henri Mondor (Créteil, France)“

Autor: Grafiati

Veröffentlicht am 27. Juli 2024

Zuletzt aktualisiert am 29. Juli 2024

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Hopital Henri Mondor (Créteil, France)" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Hopital Henri Mondor (Créteil, France)"

Matimbo, Jean Jacques Koyondele, Aliocha Natuhoyila Nkodila, Christophe Duvoux, Francky Mubenga und Antoine Wola Yaba Tshimpi. „Evaluation of survival of sickle cell patients after liver transplantation at the Henri Mondor Hospital in Créteil (HHM) in France: A Retrospective cohort study“. Gastroenterology & Hepatology: Open access 13, Nr. 3 (24.06.2022): 115–19. http://dx.doi.org/10.15406/ghoa.2022.13.00509.

Der volle Inhalt der Quelle

Annotation:

Background: Hepatic cholestasis is very common in sickle cell disease, thus requiring liver transplantation; but this technique is not practiced in the developing world. The objective of this study was to evaluate the survival of sickle cell patients after liver transplantation followed at the Henri Mondor Hospital in Créteil (HHM) in France. Methods: Historical cohort study conducted in 24 sickle cell patients followed at the Henri Mondor hospital in Créteil in France during the period from 1991 to 2019. The clinical, biological and evolutionary parameters were studied. Patient survival was described by Kaplan Meier curves and risk factors for death were sought by Cox regression. Results: Among the 24 sickle cell patients who underwent a liver transplant, 11 had died, representing a mortality rate of 45.8%. Their average age was 35.7±8.6 years, female sex ratio 1M/2F. Malnutrition accounted for 25%, 58.3% of patients were homozygous, in hepatic presentation, 45.8% were grade 0 and 54.2% grade I-V. Ascites, hepatic encephalopathy and high risk according to the MIELD score had influenced death (p<0.05). The median time to intervention was longer in the deceased (p<0.001), on the other hand, the duration of follow-up was shorter in the deceased (p<0.001). After adjustment, male gender (HRa: 3.95 95% CI: 1.42-9.00), homozygous status (HRa: 3.92 95% CI: 1.61-5.12), encephalopathy 2.70 (1.41-7.01), MELD score high risk (3.20 (1.26-5.66) and time to intervention ≥ 3 days (HRa: 2.96 95% CI: 1.89-6.78) were the independent predictors of sickle cell mortality. Conclusion: the death rate is high in transplanted sickle cell patients; it is influenced by the state of the liver, the time to intervention and the homozygote state.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Pawlotsky, Jean-Michel. „What next for hepatitis B therapy? An interview with Jean-Michel Pawlotsky“. Future Virology 14, Nr. 8 (August 2019): 507–8. http://dx.doi.org/10.2217/fvl-2019-0064.

Der volle Inhalt der Quelle

Annotation:

Biography In this exclusive interview, Jean-Michel Pawlotsky discusses present-day and developing therapies for treating hepatitis B viral infection, with a view for future directions and predictions for this currently incurable disease. This interview was conducted by Ellen Colvin, Editor of Future Virology. Dr Jean-Michel Pawlotsky is a Professor of Medicine at the University of Paris-Est, France. He is the Director of the National Reference Center for Viral hepatitis B, C and D and of the Department of Virology at the Henri Mondor University Hospital in Créteil, France, and the Director of Research Team “Viruses-Hepatology-Cancers” at the Mondor Institute of Biomedical Research (INSERM U955). Dr Pawlotsky earned his medical degree in Hepatology and Gastroenterology in 1992. Furthermore, he earned a thesis in molecular virology from the University of Paris, France, and is a graduate in virology and microbiology. Dr Pawlotsky acted as the Secretary General of the European Association for the Study of the Liver (EASL) between 2005 and 2009. He is a member of the Strategic Committee of the National Agency for Research on AIDS and Viral Hepatitis (ANRS). Dr Pawlotsky's noted career contributions include 500 published articles and book chapters and over 650 invited lectures at international meetings.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Gellen, Barnabas, Silvia Oghina, Mijiti Wuliya, Habib Ben Eljah, Soulef Guendouz, Sandrine Peyrot, Pierre Vladimir Ennezat et al. „Feasibility of Cardiac Exercise Rehabilitation in Patients with Cardiac Amyloidosis“. European Rehabilitation Journal 1, Nr. 3 (2023): 1–8. http://dx.doi.org/10.52057/erj.v3i1.27.

Der volle Inhalt der Quelle

Annotation:

Objective: We aimed to determine if prescribed exercise programs in rehabilitation of patients with cardiac amyloidosis was feasible and beneficial. Methods: This prospective monocentric pilot study was proposed to all adult patients, diagnosed with cardiac amyloidosis, and referred to the cardiac rehabilitation centre at the Henri Mondor University hospital (Créteil, France) between 2011 to 2015. All patients had clinical evaluations, laboratory tests, and echocardiographic examinations upon recruitment to the study. The cardiac exercise rehabilitation programme, in this study, comprised a baseline incremental system-limited exercise test followed by 20 endurance training sessions at a constant workload intensity. Cardiac exercise rehabilitation was deemed feasible if the patient completed the baseline test and 10 sessions without an adverse event. Patients with a relative increase of 16% in VO2max and/or maximal workload were considered to have benefited from cardiac exercise rehabilitation. Results: Overall, 27 cardiac amyloidosis patients were recruited. Cardiac exercise rehabilitation was feasible in 19 (70%) and not feasible in 8 (30%). Of the 19 patients whom cardiac exercise rehabilitation was feasible, cardiac exercise rehabilitation benefited 9 (47%). This benefit was significantly associated with lower N-type pro-brain natriuretic peptide levels, lower creatinineamia, and higher left ventricular ejection fraction at baseline. Conclusion: Cardiac exercise rehabilitation is feasible and beneficial in selected patients with cardiac amyloidosis.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Bernal, Juan, und Jacques Nunez. „Thyroid hormones and brain development“. European Journal of Endocrinology 133, Nr. 4 (Oktober 1995): 390–98. http://dx.doi.org/10.1530/eje.0.1330390.

Der volle Inhalt der Quelle

Annotation:

Bernal J, Nunez J. Thyroid hormones and brain development. Eur J Endocrinol 1995;133:390–8. ISSN 0804–4643 Thyroid hormone is a major physiological regulator of mammalian brain development. Cell differentiation, migration and gene expression are altered as a consequence of thyroid hormone deficiency or excess. The physiological role of thyroid hormone can perhaps be defined so as to ensure the timed coordination of different developmental events through specific effects on the rate of cell differentiation and gene expression. All triiodothyronine (T3) receptor isoforms are expressed in the brain and their spatial and temporal patterns of expression suggest unique and complementary functions for the different isoforms. Cell biology studies suggest a role for T3 and its receptors in oligodendroglial and neuronal differentiation and the control of cell death. Some of the effects on neuronal differentiation might be due to an action of thyroid hormone on the production of neurotropins and their receptors. In recent years a number of T3-dependent genes have been identified in the rat brain, such as myelin protein-encoding genes or specific neuronal genes, and thyroid hormone-responsive elements have been demonstrated in some of these genes. The identification of the gene network regulated by thyroid hormone during brain development, the elucidation of the mechanism of regulation and the clarification of the physiological roles of the regulated genes remain major goals for future studies. Jacques Nunez, INSERM U282. Hôpital Henri Mondor, 94010 Créteil, France

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Couette, Maryline, Stéphanie Forté, Damien Oudin Doglioni, Armand Mekontso-Dessap, David Calvet, Kevin H. M. Kuo und Pablo Bartolucci. „Early Strokes Are Associated with More Global Cognitive Deficits in Adults with Sickle Cell Disease“. Journal of Clinical Medicine 12, Nr. 4 (17.02.2023): 1615. http://dx.doi.org/10.3390/jcm12041615.

Der volle Inhalt der Quelle

Annotation:

This study sought to link neurocognitive profiles in sickle cell disease (SCD) patients with clinical characteristics. We conducted a prospective cohort study of adults with SCD who underwent comprehensive neuropsychological assessment at the UMGGR clinic at Henri Mondor Hospital, Créteil (France). A cluster analysis was performed based on neuropsychological testing scores. The association between clusters and clinical profiles was assessed. Between 2017 and 2021, 79 patients with a mean age of 36 [range 19–65] years were included. On principal component analysis, a 5-factor model presented the best fit (Bartlett’s sphericity test [χ2 (171) = 1345; p < 0.001]), explaining 72% of the variance. The factors represent distinct cognitive domains and anatomical regions. On hierarchical classification, three clusters emerged. Cluster 1 (n = 24) presented deficits in all five factors compared to Cluster 3 (n = 33). Cluster 2 (n = 22) had deficits in all factors, but to a lesser extent than Cluster 1. MoCA scores mirrored the severity of these cognitive deficits. Age, genotype and stroke prevalence did not differ significantly between clusters. However, the time of first stroke occurrence differed significantly between Cluster 1 and 2–3: 78% of strokes occurred during childhood, whereas 80% and 83% occurred during adulthood in Clusters 2 and 3, respectively. Educational attainment was also reduced in Cluster 1. SCD patients with childhood stroke seem to be at increased risk of a global cognitive deficit profile. In addition to existing methods of primary and secondary stroke prevention, early neurorehabilitation should be prioritized in order to reduce the long-term cognitive morbidity of SCD.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Kane, Christopher. „Commentary on “Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy.” Campeggi A, Xylinas E, Ploussard G, Ouzaid I, Fabre A, Allory Y, Vordos D, Abbou CC, Salomon L, de la Taille A, Institut National de la Sante et de la Recherche Medicale Unit 955 EQ7, Department of Urology, APHP, CHU Henri Mondor, Créteil, France“. Urologic Oncology: Seminars and Original Investigations 31, Nr. 2 (Februar 2013): 274–75. http://dx.doi.org/10.1016/j.urolonc.2013.02.004.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Forté, Stéphanie, Maryline Couette, Damien Oudin Doglioni, Denis Soulieres, Kevin H. M. Kuo und Pablo Bartolucci. „Evidence of Educational Bias in Cognitive Screening of Adults with Sickle Cell Disease: Comparison of Available Tools and Possible Strategies for Mitigation“. Blood 136, Supplement 1 (05.11.2020): 13–14. http://dx.doi.org/10.1182/blood-2020-143169.

Der volle Inhalt der Quelle

Annotation:

Background: Cognitive impairment is a dreaded complication of sickle cell disease (SCD) that impacts quality of life, school performance and employment. In 2020, the American Society of Hematology issued a strong recommendation that clinicians supervising the care of adults with SCD conduct surveillance for cognitive impairment using simplified signaling questions (DeBaun, 2020). However, guidance on the optimal screening strategy is lacking and several available tools are biased by language and education. The Rowland Universal Dementia Assessment Scale (RUDAS) was specifically designed for cognitive screening in multicultural populations (Storey, 2004). In the general elderly population, RUDAS is less biased by education than the Montreal Cognitive Assessment (MoCA) (Naqvi, 2015). Hypothesis: In adults with SCD, performance on the RUDAS is less influenced by educational attainment when compared to the MoCA. Our primary aim was to estimate the prevalence of suspected cognitive impairment using RUDAS and MoCA in adult SCD patients. The secondary aims were to examine for the presence of educational bias and to develop mitigation strategies in case of such a bias. Methods: Study design: cross-sectional study at UMGRR clinic at Henri Mondor Hospital, Créteil (France). Inclusion criteria: out-patients ≥18 years-old; all SCD phenotypes. Exclusion criteria: inability to obtain informed consent and/or follow study instructions. Intervention: Cognitive screening was performed using the RUDAS (translated to French by Philippe Desmarais), MoCA (third alternative version) and an additional visuospatial task of copying overlapping triangles (from the French BEC96 assessment). RUDAS and MoCA scores <28 and <26, respectively, were considered suggestive of cognitive impairment per previous studies (Basic, 2009 and Nasredinne, 2005) and patients were referred for definite neuropsychological evaluation. Survey on demographics and screening for depression and anxiety using Hospital Anxiety Depression Scale (HADS) were completed by the participants. Educational attainment was scored based on the number of years of schooling for the highest completed diploma. Statistical plan: linear regression was performed to identify possible associations between RUDAS, MoCA and social determinants of health. Results: Among the first 45 consecutive adult SCD patients undergoing routine cognitive screening, the median age was 39 (range 19-67). RUDAS and MoCA scores suggestive of mild cognitive impairment were found in 33/45 (73.3%) and 29/45 (64.4%) participants, respectively. There was a strong correlation between both tests (r=0.48, p=0.001). Both RUDAS and MoCA scores increased significantly with increasing level of education (r=0.36, p=0.015 and r=0.39, p=0.007, respectively), but were not significantly influenced by the HADS score. RUDAS and MoCA test items most biased by education were visuoconstructional tasks. Tasks assessing executive functioning and language were also biased in MoCA. Substituting the 3D visuospatial task of the RUDAS by a 2D task reduced the educational bias (r=0.20, p=0.045). Adding 1 point for highest level of education £ 12 years after kindergarten did significantly mitigate the effect of education on the RUDAS but only partially for the MoCA (r=0.23, p=0.131 and r=0.30, p=0.047). Conclusions: Overall, these results suggest there is an educational bias in the neurocognitive screening of adult SCD patients using available tools such as the RUDAS and MoCA. Although RUDAS was less biased overall, visuospatial assessment remained biased. The task often considered more "culture-fair" is still subject to the impact of educational potential (Statucka, 2019). We provide different strategies to mitigate education bias when assessing with RUDAS. Thus, the RUDAS adjusted by the educational level allows to systematically identify SCD patients in need of comprehensive neurocognitive testing. Prospective validation is ongoing. Disclosures Forté: Canadian Hematology Society: Research Funding; Pfizer - Global Medical Grants: Research Funding. Soulieres:Novartis: Research Funding; BMS: Membership on an entity's Board of Directors or advisory committees. Kuo:Pfizer: Consultancy, Research Funding; Celgene: Consultancy; Alexion: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Bioverativ: Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bluebird Bio: Consultancy; Apellis: Consultancy. Bartolucci:Roche: Consultancy; Innovhem: Other; AGIOS: Consultancy; Bluebird: Consultancy; Emmaus: Consultancy; Addmedica: Research Funding; Fabre Foundation: Research Funding; Novartis: Research Funding; Bluebird: Research Funding; GBT: Consultancy; ADDMEDICA: Consultancy; HEMANEXT: Consultancy; Novartis: Consultancy.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Peters, Marion G., H. W. Hann, Paul Martin, E. Jenny Heathcote, P. Buggisch, R. Rubin, M. Bourliere et al. „Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).“ Gastroenterology 126, Nr. 1 (Januar 2004): 91–101. http://dx.doi.org/10.1053/j.gastro.2003.10.051.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Couette, Maryline, Stéphanie Forté, Damien Oudin Doglioni, Kevin H. M. Kuo und Pablo Bartolucci. „Cognitive Profile of Adults with Sickle Cell Disease - Cluster Analysis“. Blood 138, Supplement 1 (05.11.2021): 3120. http://dx.doi.org/10.1182/blood-2021-150689.

Der volle Inhalt der Quelle

Annotation:

Abstract Background: Published literature on cognitive functioning in adults with sickle cell disease (SCD) is sparse when compared to children. A few reports describe deficits in processing speed and executive functioning. Some studies suggest that these deficits are more severe in patients with silent cerebral infarcts (SCI). Even in the absence of radiological evidence of ischemic injury, some cognitive deficits have been depicted in adults . We hypothesize that in SCD adults, the cognitive profile varies with the presence of ischemic injury (SCI or overt stroke). The aims of this study were 1) to describe the neuropsychological profiles of SCD adults, and 2) to characterize clusters of patients with similar cognitive profiles. Methods: We conducted a retrospective analysis of all consecutive SCD adults who underwent comprehensive neuropsychological assessment during routine care at the UMGGR clinic at Henri Mondor Hospital, Créteil (France), between January 2017 and April 2021. The Montreal Cognitive Assessment (MoCA) and Hospital Anxiety and Depression Scale (HADS) were used for cognitive disorder, anxiety and depression screening, respectively. The cognitive battery combined standardized neuropsychological tests with established clinical utility and validity. Educational attainment was scored based on the number of years of schooling for the highest completed diploma. Principal component analysis was performed. ANOVA was used to compare patients' characteristics between clusters. Results: 80 patients, median age 36.5 [range 19-63] years were included. 40 (50.0%) were male. Genotype distribution was 62 patients (77.5%) with SS/Sbeta 0, 12 (15.0%) with SC and 6 (7.5%) with Sbeta +. On Principal Component Analysis, a 5-factor model presented the best fit (Bartlett's sphericity test (χ²(171)=1174; p<0.001)), explaining 71.8% of the variance in neuropsychological scores. The first factor encompassed tests specifically assessing visual attention/visual organization (right hemisphere). The second included tests for mental/cognitive control (frontal lobe), the third tests of selective inhibition/attention (fronto-parietal), the fourth tests for language/memory (left temporal lobe) and the last referred to shifting skill (sub-cortical loop). On hierarchical classification, 3 different clusters emerged: 32 patients in cluster 1, 32 in cluster 2 and 16 in cluster 3. Cluster 1 had a lower mean educational level (F(2,77) = 15,65; p<0,001). Cluster 1 showed the lowest mean MoCA score (20.0/30.0), relative to cluster 2 and 3 (24.6 and 26.4; p<0.001 and p<0.001, respectively). Cluster 1 patients presented deficits on all five factors. Cluster 2 patients compared to cluster 3 were altered in 4 factors (factors 1-4), but to a lesser extent than cluster 1. Processing speed was slower and some frontal-executive deficits were present in cluster 2 compared to cluster 3. There was no statistical difference between clusters in terms of ethnic origins. There was a trend for the presence of more cerebral vasculopathy in cluster 1 (chi2; p=0.06). Regarding stroke, 70% occurred during childhood in cluster 1, whereas 70% during adulthood in cluster 2, and 100% during adulthood in cluster 3. Conclusions: Overall, these results suggest at least three different cognitive profiles in adults with SCD: 1) few or no cognitive deficits (cluster 3), 2) some cognitive impairment with a sub-cortical cognitive profile (cluster 2) and 3) more global cognitive impairment with cortical/sub-cortical profile and specific deficits of memory, language and constructional praxis, depending on the location of prior overt neurological events (cluster 1). To reduce the long-term cognitive morbidity of SCD, patients can be identified by their distinct cognitive profiles and neurorehabilitation tailored to their unique profile should be applied. The large proportion of childhood stroke in patients with global cognitive impairment in contrast with majority of those with milder to no cognitive impairment having had their stroke in adulthood emphasize the crucial importance of preventing early childhood stroke and implementing early neurorehabilitation. Disclosures Forté: Canadian Hematology Society: Research Funding; Pfizer: Research Funding; Novartis: Honoraria. Kuo: Pfizer: Consultancy, Research Funding; Bluebird Bio: Consultancy; Novartis: Consultancy, Honoraria; Apellis: Consultancy; Alexion: Consultancy, Honoraria; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy; Bioverativ: Membership on an entity's Board of Directors or advisory committees. Bartolucci: Jazz Pharma: Other: Lecture fees; AGIOS: Consultancy; Emmaus: Consultancy; GBT: Consultancy; F. Hoffmann-La Roche Ltd: Consultancy; Hemanext: Consultancy; INNOVHEM: Other: Co-founder; Bluebird: Consultancy, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Lecture fees, Steering committee, Research Funding; Fabre Foundation: Research Funding; Addmedica: Consultancy, Other: Lecture fees, Research Funding.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

„Comité de l'Antibiogramme de la Société Française de Microbiologie Report 20031,21This publication is protected by copyright. No part or translation of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Chairholder of Comité de l'Antibiogramme de la Société Française de Microbiologie, Centre Hospitalier Universitaire Henri Mondor, Service de Bactériologie-Virologie-Hygiène, 51, ave du Mal de Lattre de, Tassigny, 94010 Créteil Cedex, France. The Comité de l'Antibiogramme hereby grants permission to reproduce this publication for use in laboratory procedure manuals at a single site, and limited portions of this publication for scientific purposes.2Members (2002): G. Carret, J.D. Cavallo, H. Chardon, C. Chidiac, P. Choutet, P. Courvalin, H. Dabernat, H. Drugeon, L. Dubreuil, F. Goldstein, V. Jarlier, R. Leclercq, M.H. Nicolas-Chanoine, A. Philippon, C. Quentin-Noury, B. Rouveix, J. Sirot, C.J. Soussy.“ International Journal of Antimicrobial Agents 21, Nr. 4 (April 2003): 364–91. http://dx.doi.org/10.1016/s0924-8579(03)00021-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Dissertationen zum Thema "Hopital Henri Mondor (Créteil, France)"

Livache, Karine. „Préparation centralisée des anticancéreux à l'hôpital Henri Mondor : intérêt économique“. Paris 5, 1991. http://www.theses.fr/1991PA05P107.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!